MedTrace Logo

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

NCT07758634 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-08-11

No results posted yet for this study

Summary

A Study of CTX340 in Participants with Uncontrolled Hypertension.

Conditions

Interventions

DRUG

CTX340

CTX340 is an in vivo gene editing therapy designed to utilize clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) to target and disrupt human angiotensinogen (AGT) gene in liver.

DRUG

Placebo

One of the arms in Phase 2 will be placebo.

Sponsors & Collaborators

  • CRISPR Therapeutics AG

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-08
Primary Completion
2028-07-01
Completion
2029-07-01
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07758634 on ClinicalTrials.gov